Immunotherapy doubles amount of time head and neck cancer patients are disease free, study results suggest

Immunotherapy treatment pembrolizumab (Keytruda; Merck Sharp & Dohme) helps patients with head and neck cancers to live extra years disease free when compared with standard treatment, according to the results of a study. The phase III trial’s findings, which were presented at the American Society of Clinical Oncology annual meeting on 30 May 2025, demonstrated […]